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Impact of Sex on Clinical and Angiographic
Outcomes Among Patients Undergoing
Revascularization With Drug-Eluting Stents
Giulio G. Stefanini, MD,* Bindu Kalesan, MSC,†‡ Thomas Pilgrim, MD,* Lorenz Räber, MD,*
oshinobu Onuma, MD,§ Sigmund Silber, MD, Patrick W. Serruys, MD,§
ernhard Meier, MD,* Peter Jüni, MD,†‡ Stephan Windecker, MD*†
ern, Switzerland; Rotterdam, the Netherlands; and Munich, Germany
Objectives The goal of this study was to investigate sex-based differences in long-term clinical and
angiographic outcomes after coronary revascularization with drug-eluting stents (DES).
Background The impact of sex on clinical and angiographic outcomes following revascularization
with DES is not well established.
Methods Individual patient data from 3 all-comers randomized DES trials (SIRTAX, LEADERS, RESOLUTE All-
Comers) were pooled. Of 5,011 patients, 4,885 (97.5%) completed 2-year follow-up (1,164 women, 3,721 men).
Protocol-mandated angiographic follow-up was available for 1,561 lesions (351 among women, 1,210 among
men). The primary endpoint was the composite of cardiac death and myocardial infarction (MI) at 2 years.
Results At baseline, women, as compared with men, were older, more frequently had diabetes, obesity, and
hypertension, less frequently had smoking habits, previous MI, and previous surgical revascularization, and had
a smaller reference diameter of the target vessel as well as a lower SYNTAX score. After adjustment for base-
line differences, women and men had a similar risk of cardiac death or MI (odds ratio [OR]: 1.13, 95% conﬁ-
dence interval [CI]: 0.82 to 1.56, p  0.44), cardiac death (OR: 1.04, 95% CI: 0.61 to 1.80, p  0.87), and MI (OR:
1.07, 95% CI: 0.75 to 1.53, p  0.71) at 2 years. Similarly, risks of target lesion revascularization (OR: 1.09, 95%
CI: 0.77 to 1.54, p  0.62), target vessel revascularization (OR: 0.88, 95% CI: 0.63 to 1.22, p  0.43), and deﬁnite
or probable stent thrombosis (OR: 0.73, 95% CI: 0.38 to 1.38, p  0.33) were comparable for women and men.
Follow-up angiography showed no differences in terms of in-stent late loss (0.18  0.54 mm vs.
0.20  0.99 mm, p  0.76) and in-segment binary restenosis (8.5% vs. 8.5%, p  0.76).
onclusions The unrestricted use of DES is associated with similar long-term safety and efﬁcacy
mong women and men with coronary artery disease. (Sirolimus-Eluting Versus Paclitaxel-Eluting
tents for Coronary Revascularization [SIRTAX]; NCT00297661, LEADERS Trial Limus Eluted From A
urable Versus ERodable Stent Coating [LEADERS]; NCT00389220, RESOLUTE-III All-comers Trial: A
andomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percu-
aneous Coronary Intervention [RESOLUTE All-Comers]; NCT00617084) (J Am Coll Cardiol Intv 2012;
:301–10) © 2012 by the American College of Cardiology Foundation
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302More than 1 million percutaneous coronary interventions
(PCI) are performed each year in the United States with
one-third of procedures performed in women (1). Female
patients differ from their male counterparts in terms of age
(2), cardiovascular risk factors (3), clinical presentation
(4,5), and angiographic characteristics, including vessel size
and extent of disease (4,6). Early studies during the balloon
angioplasty era reported a lower procedural success, a higher
in-hospital mortality, and impaired long-term clinical
outcomes among women compared with men (2,3,7,8).
See page 311
Bare-metal stents improved outcomes after PCI among
women (4,9–12) in terms of safety and efficacy. The advent
of drug-eluting stents (DES) has led to important reduc-
tions in restenosis and repeat revascularization rates com-
pared with bare-metal stents (13), and DES are used in
more than 80% of patients undergoing PCI in the United
States (1). However, sex-related differences in clinical and
angiographic outcomes after revascularization with DES
are not well established (14 –17). We therefore pooled
individual patient data from 3 re-
cent all-comers randomized clinical
trials with the unrestricted use of
DES (Sirolimus-Eluting Versus
Paclitaxel-Eluting Stents for Coro-
nary Revascularization [SIRTAX];
LEADERS Trial Limus Eluted
From A Durable Versus ERodable
Stent Coating [LEADERS];
RESOLUTE-III All-comers Tri-
al: A Randomized Comparison of a Zotarolimus-Eluting Stent
With an Everolimus-Eluting Stent for Percutaneous Coronary
Intervention [RESOLUTE All-Comers]) (18–20) and com-
pared clinical and angiographic outcomes between women and
men during long-term follow-up through 2 years.
Methods
Study population. Individual data were pooled for 5,011
atients from 3 large randomized clinical trials investigating
he unrestricted use of DES for coronary revascularization:
he SIRTAX trial (18), the LEADERS trial (19), and the
ESOLUTE All-Comers trial (20). All trials were con-
ucted between 2004 and 2009 at European institutions,
ith the exclusive use of DES and an all-comers study
esign. Inclusion criteria were broad to reflect routine
linical practice. Patients with either stable coronary artery
isease or acute coronary syndrome (including patients with
nstable angina, non–ST-segment elevation and ST-
egment elevation myocardial infarction) were eligible, if
hey had at least 1 lesion with diameter stenosis of 50% or more
Abbreviations
and Acronyms
CI  confidence interval
DES  drug-eluting stent(s)
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary interventionn a vessel with reference diameter of 2.25 to 4.0 mm (SIRTAX And RESOLUTE All-Comers) and 2.25 to 3.5 mm (LEAD-
RS) (18–20). None of the trials had any restriction with
espect to number of treated lesions, treated vessels, lesion
ength, or number of stents implanted. Exclusion criteria were
ew and included known intolerance to the study drugs, metal
lloys, or contrast media, planned surgery within 6 months
fter the index procedure, and participation in another study.
ngiographic follow-up was planned at 8 months among
atients included in SIRTAX, at 9 months among 25% of
atients included in LEADERS, and at 13 months among
0% of patients in RESOLUTE All-Comers. The trials
omplied with the provisions of the Declaration of Helsinki,
nd the study protocols were approved by the institutional
eview board at each study center. All patients provided written
nformed consent for participation in the study.
Procedures. Randomization was done after diagnostic an-
iography and before PCI in all 3 trials. In the SIRTAX
rial (18), patients were randomly allocated to receive
irolimus-eluting stents (Cypher, Cordis, Johnson & Johnson,
iami Lakes, Florida) or paclitaxel-eluting stents (Taxus,
oston Scientific, Natick, Massachusetts); in the LEADERS
rial (19), patients were randomly allocated to receive biolimus-
luting stents (BioMatrix, Biosensors, Newport Beach, Cali-
ornia) or sirolimus-eluting stents (Cypher, Cordis); and in the
ESOLUTE All-Comers trial (20), patients were randomly
llocated to receive zotarolimus-eluting stents (Resolute En-
eavor, Medtronic, Santa Rosa, California) or everolimus-
luting stents (Xience V, Abbott Vascular, Santa Clara, Cali-
ornia). Balloon angioplasty and stent implantation were
erformed according to standard techniques and in accordance
ith guidelines; direct stenting was allowed. Full lesion cover-
ge was attempted by implanting 1 or several stents. No
ixture of type of stents was permitted for a given patient
nless the operator was unable to insert the study stent, in
hich case crossover to another device of the operator’s choice
as possible. In case of unplanned revascularization procedures
equiring stent implantation, it was recommended that physi-
ians use the same type as the initially allocated study stent.
rocedural anticoagulation was achieved with unfractionated
eparin at a dose of 5,000 IU or 70 to 100 IU/kg of body
eight; the use of glycoprotein IIb/IIIa inhibitors was left to
he operator’s discretion. Dual antiplatelet therapy consisting
f acetylsalicylic acid of at least 75 mg once daily and the
hienopyridine clopidogrel 75 mg daily was prescribed for at
east 12 months in the SIRTAX and LEADERS trials, and
or at least 6 months in the RESOLUTE All-Comers trial.
Deﬁnitions. The primary endpoint of the present study was
he composite of cardiac death and myocardial infarction (MI)
t 2 years. Secondary clinical endpoints were the individual
omponents of the primary endpoint as well as all-cause death,
he composite of all-cause death and MI, clinically indicated
arget lesion and target vessel revascularization, and definite
nd definite or probable stent thrombosis according to the
cademic Research Consortium criteria (21).
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303For each trial, a blinded clinical events committee inde-
pendently adjudicated all adverse events. Endpoint defini-
tions were comparable across the 3 trials. Cardiac death was
defined as death from cardiac causes or any death from
unknown causes in SIRTAX and LEADERS, and as any
death unless an undisputed noncardiac cause was present in
RESOLUTE All-Comers. MI was defined—in SIRTAX
and LEADERS trials—as the presence of new Q waves
in at least 2 contiguous leads and an elevated creatine
kinase-MB fraction, or—in the absence of significant Q
waves—as an increase in the creatine kinase level to more
than twice the upper limit of the normal range with an
elevated level of creatine kinase-MB or troponin (18,19).
In the RESOLUTE All-Comers trial, MI was defined
according to an “extended historical” definition (20,22),
consistent with the 1 used in SIRTAX and LEADERS.
Target lesion revascularization was defined as any revas-
cularization for a stenosis within the stent or within a
5-mm border proximal and distal to the stent in all 3
trials. A revascularization was considered clinically indi-
cated in the presence of angiographic diameter stenosis of
at least 50% and ischemic signs or symptoms, or with
angiographic diameter stenosis of at least 70% regardless
of ischemic signs or symptoms (18 –20).
Secondary angiographic endpoints were late lumen loss
(i.e., difference between the post-procedure and follow-up
minimal lumen diameter), rate of binary restenosis (i.e., %
diameter stenosis of at least 50%), percent diameter stenosis
Table 1. Baseline Clinical Characteristics
(
Age, yrs
Cardiac risk factors
Diabetes
Insulin-requiring diabetes
Obese
Hypertension
Hypercholesterolemia
Serum creatinine 2.0 mg/l
Current smoking
Clinical history
Previous MI
Previous PCI
Previous CABG
Clinical indication to PCI
Stable coronary artery disease
Non–ST-segment elevation acute coronary syndromes
ST-segment elevation MI
Left ventricular ejection fraction 0.50
SYNTAX score
Multivessel disease
Values are mean SD or n (%).CABG coronary artery bypass graft; CI confidence interval; MImyoca(i.e., reference vessel diameter  minimal lumen diameter/
reference vessel diameter  100), and minimal lumen
diameter. Angiographic endpoints were considered for both
the in-stent (i.e., within the stent) and in-segment (i.e.,
within the stent and a 5-mm border proximal and distal)
analysis. For a detailed description of quantitative coronary
angiography methods, we refer to the principal publications
of the 3 trials (18–20). SYNTAX score was assessed by a
central core laboratory (Cardialysis, Rotterdam, the Neth-
erlands) in all 3 trials.
Statistical analysis. Of 5,011 patients randomized in the 3
rials, 4,885 (97.5%) patients completed 2 years of
ollow-up according to the pre-specified definition (i.e.,
ast medical contact 720 days after the index procedure,
ith a 30-day window) and were included in the present
nalysis. Comparison between women and men were
arried out using mixed models with random effects
pecified as type of randomized clinical trial as random
ntercept, and treatment arms as random coefficients.
ixed maximum logistic regression models were used to
erive differences between female and male patients for
inary and continuous outcomes, respectively. The per-
entages were predicted probabilities derived from mixed
aximum logistic regression models. Means and stan-
ard deviations were predicted values derived from mixed
aximum likelihood regression models. Odds ratios
ORs) and confidence intervals (CIs) were adjusted for
tent type in the crude analysis, whereas the adjusted
en
,164)
Men
(n  3,721) Difference (95% CI) p Value
0.5) 63.0 (10.7) 4.09 (3.39 to 4.79) 0.001
7.1) 804 (21.6) 5.46 (2.66 to 8.25) 0.001
2.6) 253 (31.5) 11.08 (4.86 to 17.31) 0.001
8.9) 903 (24.4) 4.52 (1.64 to 7.40) 0.001
6.4) 2,531 (68.0) 8.36 (5.28 to 11.44) 0.001
4.5) 2,426 (65.2) 0.68 (3.37 to 2.01) 0.62
.3) 57 (1.6) 0.26 (1.08 to 0.55) 0.52
3.4) 1,067 (28.7) 5.31 (8.33 to2.29) 0.001
4.7) 1,186 (32.2) 7.51 (10.55 to4.46) 0.001
9.0) 1,173 (31.5) 2.49 (5.21 to 0.23) 0.07
.3) 428 (11.5) 5.23 (7.25 to3.21) 0.001
0.29
6.4) 1,738 (46.7) 0.32 (0.90 to 0.27)
8.1) 1,321 (35.5) 2.64 (2.22 to 7.50)
5.5) 662 (17.8) 2.33 (6.61 to 1.95)
1.1) 581 (22.5) 1.43 (4.70 to 1.84) 0.39
8.4 13.8 8.7 0.95 (1.55 to0.34) 0.001
4.1) 980 (26.3) 2.25 (5.37 to 0.87) 0.39Wom
n  1
67.1 (1
315 (2
134 (4
336 (2
889 (7
751 (6
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73 (6
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280 (2rdial infarction; PCI percutaneous coronary intervention.
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304analysis was performed using multivariable models, ad-
justing for baseline variables showing differences (p 
0.2) between women and men, including: stent type, age,
diabetes, body mass index, hypertension, current smok-
ing, previous MI, previous PCI, previous coronary artery
bypass surgery, SYNTAX score, lesion length, pre-
procedural reference vessel diameter, and pre-procedural
stenosis.
Results
Of 5,011 patients randomized in the 3 trials, 4,885 (97.5%)
patients completed 2 years of follow-up and were included
Table 2. Angiographic Characteristics and Procedura
Women
(n  1,164)
No. of vessels treated per patient 1.2 (0.5)
Allocated stent type
Sirolimus-eluting stent 336 (28.9)
Paclitaxel-eluting stent 108 (9.3)
Biolimus-eluting stent 208 (17.9)
Zotarolimus-eluting stent 260 (22.3)
Everolimus-eluting stent 252 (21.6)
No. of lesions 1,615
Target vessel
Left main 23 (1.4)
Left anterior descending 678 (42.0)
Left circumﬂex 377 (23.3)
Right coronary artery 521 (32.3)
Bypass graft 16 (1.0)
Lesion characteristics
De novo lesions 1,500 (93.6)
Total occlusion 203 (12.7)
Moderate or severe calciﬁcation 337 (21.1)
Lesion length, mm 12.24 10.30
Stent characteristics
No. of stents per lesion 1.2 (0.7)
Average stent diameter, mm 2.84 0.52
Total stent length per lesion, mm 19.93 13.00
Angiographic ﬁndings
Pre-procedure
RVD, mm 2.60 0.66
MLD, mm 0.79 0.60
Stenosis, % 69.3 21.0
Post-procedure
MLD, mm
In-stent 2.40 0.59
In-segment 2.17 0.63
Stenosis, %
In-stent 11.6 11.3
In-segment 18.3 13.0
Values are mean SD or n (%).CI confidence interval; MLDminimal lumen diameter; RVD referencin the present analysis: 1,164 (23.8%) women and 3,721
(76.2%) men. At baseline, women, as compared with men,
were older (67.1  10.5 years vs. 63.0  10.7 years, p 
.001), more frequently had diabetes (27.1% vs. 21.6%, p 
.001), obesity (28.9% vs. 24.4%, p  0.001), and hyper-
ension (76.4% vs. 68.0%, p  0.001), less frequently had
moking habits (23.4% vs. 28.7%, p  0.001), prior MI
24.7% vs. 32.2%, p  0.001), and prior coronary artery
ypass surgery (6.3% vs. 11.5%, p 0.001), and had a lower
ngiographic complexity as assessed by the SYNTAX score
12.9  8.4 vs. 13.8  8.7, p  0.001) (Table 1).
ngiographic and procedural characteristics are shown in
able 2. Women had a smaller reference diameter of the
ults
Men
n  3,721)
Difference
(95% CI) p Value
1.2 (1.0) 0.03 (0.06 to 0) 0.10
0.09
1,001 (26.9) 1.96 (0.34 to 4.26)
397 (10.7) 1.39 (3.02 to 0.24)
630 (16.9) 0.94 (0.16 to 2.04)
838 (22.5) 0.18 (0.40 to 0.03)
855 (23.0) 1.33 (2.88 to 0.23)
5,448
0.62
83 (1.5) 0.10 (0.50 to 0.30)
2,175 (39.9) 2.06 (6.16 to 10.28)
1,331 (24.4) 1.09 (5.43 to 3.25)
1,710 (31.4) 0.87 (2.61 to 4.35)
149 (2.7) 1.74 (8.71 to 5.22)
5,056 (93.3) 0.29 (1.10 to 1.68) 0.68
705 (13.1) 0.46 (2.34 to 1.42) 0.63
1,108 (20.6) 0.50 (1.76 to 2.76) 0.66
2.60 17.05 0.36 (0.86 to 0.14) 0.16
1.2 (1.5) 0.01 (0.03 to 0.05) 0.49
2.93 0.95 0.09 (0.11 to0.06) 0.001
0.79 23.83 0.86 (1.50 to0.22) 0.01
2.71 1.21 0.11 (0.15 to0.08) 0.001
0.79 1.10 0.00 (0.03 to 0.03) 0.94
70.5 38.5 1.26 (2.30 to0.23) 0.02
2.48 1.08 0.07 (0.10 to0.04) 0.001
2.25 1.17 0.08 (0.12 to0.05) 0.001
2.32 20.6 0.71 (1.26 to0.16) 0.01
8.26 24.1 0.05 (0.62 to 0.72) 0.89l Res
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305target vessel than men (2.60  0.66 mm vs. 2.71  1.21
m, p  0.001), and had a smaller percent stenosis of the
arget lesion (69.3  21.0% vs. 70.5  38.5%, p  0.02).
he randomly allocated type of stent was comparable
etween women and men.
Clinical outcomes at 30 days and 2 years are reported in
ables 3 and 4. At 2 years of follow-up, women, as
ompared with men, had a similar risk of cardiac death or
I (8.3% vs. 6.6%, adjusted OR: 1.13, 95% CI: 0.82 to
.56, p  0.44) in adjusted analyses. The individual
omponents of the primary endpoint cardiac death (2.9%
Table 3. Clinical Outcomes at 30 Days
Women
(n  1,164)
Men
(n  3,72
Death 13 (1.1) 20 (0.5
Cardiac death 10 (0.9) 18 (0.5
MI 52 (4.5) 132 (3.6
Q-wave 10 (0.9) 23 (0.6
Non–Q-wave 42 (3.6) 110 (3.0
Clinically indicated TVR 22 (1.9) 59 (1.6
Percutaneous 20 (1.7) 52 (1.4
Surgical 2 (0.2) 8 (0.2
Clinically indicated TLR 21 (1.8) 53 (1.4
Percutaneous 19 (1.6) 46 (1.2
Surgical 2 (0.2) 7 (0.2
Cardiac death or MI 59 (5.1) 147 (4.0
Cardiac death, MI, clinically indicated TVR 66 (5.7) 171 (4.6
Cardiac death, MI, clinically indicated TLR 66 (5.7) 166 (4.5
Values are n (%).
OR odds ratio; TLR target-lesion revascularization; TVR target-vessel revascularization; oth
Table 4. Clinical Outcomes at 2 Years
Women
(n  1,164)
Men
(n  3,72
Death 47 (4.0) 138 (3.7
Cardiac death 34 (2.9) 92 (2.5
MI 68 (5.8) 175 (4.7
Q-wave 12 (1.0) 32 (0.9
Non–Q-wave 56 (4.8) 146 (3.9
Clinically indicated TVR 75 (6.4) 280 (7.5
Percutaneous 67 (5.8) 250 (6.7
Surgical 11 (1.0) 46 (1.2
Clinically indicated TLR 71 (6.1) 222 (6.0
Percutaneous 63 (5.4) 194 (5.2
Surgical 8 (0.7) 36 (1.0
Cardiac death or MI 96 (8.3) 244 (6.6
Cardiac death, MI, clinically indicated TVR 141 (12.1) 456 (12.
Cardiac death, MI, clinically indicated TLR 139 (11.9) 403 (10.
Values are n (%).Abbreviations as in Tables 1 and 3.s. 2.5%, adjusted OR: 1.04, 95% CI: 0.61 to 1.80, p 
.87) and MI (5.8% vs. 4.7%, adjusted OR: 1.07, 95% CI:
.75 to 1.53, p  0.71) did not show differences between
women and men. The risk of clinically indicated repeat
interventions was comparable between women and men with
respect to target lesion (6.1% vs. 6.0%, adjusted OR: 1.09, 95%
CI: 0.77 to 1.54, p  0.62) and target vessel revascularization
(6.4% vs. 7.5%, adjusted OR: 0.88, 95% CI: 0.63 to 1.22, p
0.43). Adjusted risks of the primary endpoint and its compo-
nents, as well as target lesion and target vessel revascularization
at 2 years are displayed in Figure 1.
Crude Adjusted
OR (95% CI) p Value OR (95% CI) p Value
2.10 (1.04–4.23) 0.04 2.53 (0.84–7.67) 0.10
1.79 (0.82–3.90) 0.14 2.21 (0.65–7.57) 0.21
1.27 (0.91–1.76) 0.16 1.06 (0.71–1.60) 0.77
1.39 (0.66–2.93) 0.39 0.96 (0.36–2.56) 0.93
1.22 (0.85–1.76) 0.28 1.07 (0.69–1.68) 0.75
1.18 (0.72–1.94) 0.51 0.69 (0.34–1.40) 0.31
1.22 (0.72–2.05) 0.46 0.70 (0.34–1.48) 0.35
0.82 (0.17–3.86) 0.80 0.61 (0.06–5.87) 0.67
1.26 (0.75–2.09) 0.38 0.76 (0.37–1.57) 0.46
1.31 (0.76–2.24) 0.33 0.71 (0.33–1.54) 0.39
0.91 (0.19–4.41) 0.91 0.71 (0.07–6.99) 0.77
1.29 (0.95–1.76) 0.10 1.07 (0.72–1.59) 0.75
1.24 (0.93–1.67) 0.14 1.02 (0.69–1.49) 0.93
1.28 (0.96–1.72) 0.10 1.06 (0.72–1.55) 0.78
eviations as in Table 1.
Crude Adjusted
OR (95% CI) p Value OR (95% CI) p Value
1.08 (0.77–1.52) 0.65 0.99 (0.63–1.56) 0.97
1.18 (0.79–1.75) 0.43 1.04 (0.61–1.80) 0.87
1.25 (0.94–1.67) 0.13 1.07 (0.75–1.53) 0.71
1.20 (0.62–2.34) 0.59 1.02 (0.44–2.38) 0.97
1.23 (0.90–1.69) 0.20 1.04 (0.70–1.54) 0.85
0.85 (0.65–1.10) 0.22 0.88 (0.63–1.22) 0.43
0.85 (0.64–1.12) 0.25 0.85 (0.59–1.20) 0.35
0.77 (0.40–1.50) 0.45 0.98 (0.47–2.07) 0.96
1.03 (0.78–1.36) 0.84 1.09 (0.77–1.54) 0.62
1.04 (0.78–1.40) 0.78 1.08 (0.74–1.55) 0.70
0.72 (0.33–1.54) 0.39 0.84 (0.35–2.03) 0.70
1.27 (1.00–1.63) 0.05 1.13 (0.82–1.56) 0.44
0.99 (0.81–1.21) 0.89 0.98 (0.75–1.26) 0.85
1.12 (0.91–1.37) 0.29 1.13 (0.87–1.47) 0.351)
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306Cumulative events curves for definite and definite or
probable stent thrombosis stratified according to sex are shown in
Figure 2. There was no difference in the risk of stent
thrombosis between women and men in terms of definite
(1.7% vs. 1.7%, adjusted OR: 0.68, 95% CI: 0.33 to 1.39,
p  0.29) and definite or probable stent thrombosis (2.2%
vs. 2.2%, adjusted OR: 0.73, 95% CI: 0.38 to 1.38, p 
0.33) at any time point (Table 5).
Angiographic outcomes. Protocol-mandated angiographic
ollow-up was available for 1,561 lesions: 351 lesions
mong 260 women and 1,210 lesions among 876 men.
ith respect to baseline clinical characteristics, patients
ith, as compared to those without, angiographic
ollow-up were younger (62.6  10.7 vs. 64.3  10.8,
 0.001), more frequently smokers (32.7% vs. 26.1%,
 0.05), and less frequently treated with previous coronary
rtery bypass graft (4.1% vs. 10.6%, p  0.001). Crude and
djusted results of angiographic outcomes according to sex are
resented in Table 6. There were no differences in terms of
n-stent late lumen loss (0.18 0.54 mm vs. 0.20 0.99 mm,
 0.76) and in-segment binary restenosis (8.5% vs. 8.5%,
 0.76) (Fig. 3) between women and men during follow-up
ngiography. Paired angiographic findings for in-stent mini-
al lumen diameter at baseline, immediately after the inter-
ention and at the time of angiographic follow-up showed no
ifferences between women and men (Fig. 4).
iscussion
The present analysis represents the largest investigation of
sex-based clinical and angiographic outcomes in a popula-
Figure 1. Clinical Outcomes Among Women and Men
Adjusted odds ratios (OR) and 95% conﬁdence intervals (CI) for cardiac death
revascularization (TLR), and target vessel revascularization (TVR) at 2 years.tion pooled from 3 large randomized clinical trials with theunrestricted use of DES and follow-up through 2 years. Our
findings can be summarized as follows:
1. Women undergoing PCI with the unrestricted use of
DES differ from their male counterparts and are
typically older, have more cardiovascular risk factors
except for smoking, and a lower degree of angio-
graphic complexity as assessed by the SYNTAX score.
2. After controlling for baseline differences, women undergo-
ing PCI with DES have a similar risk of cardiac death and
MI as compared with men through 2 years of follow-up.
3. DES achieve equivalent safety and efficacy in women
and men with similar results in terms of stent throm-
bosis, repeat revascularization, and angiographic out-
comes through 2 years of follow-up.
Early studies evaluating sex-based differences in out-
comes after PCI in the balloon angioplasty era reported
disparate results, but in general showed worse in-hospital
and long-term clinical outcomes among women com-
pared with men, with higher rates of in-hospital mortal-
ity and more frequent recurrent angina during long-term
follow-up (2,3,7,8,23). This “gender gap” did largely
decrease with the advent of bare-metal stents. Indeed,
advances in technology leading to smaller guiding and
balloon catheters resulted in more favorable outcomes in
women with similar angiographic and procedural success
rates despite smaller vessel size (10). Moreover, the use of
bare-metal stents improved long-term outcomes among
women (4,9 –12), particularly as related to the risk of
repeat revascularization. However, women still showed a
higher risk of mortality during the short term (30 days)
ocardial infarction (MI), cardiac death, MI, clinically indicated target lesionor mythat persisted after adjustment for baseline clinical dif-
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307ferences (4), and tended to have more symptoms of
ngina as compared with men during follow-up to 1 year
24). Only a few studies are available related to sex-based
ifferences using DES (14 –17). Lansky et al. (14) and
olinas et al. (15) observed a similar benefit among
omen and men in terms of angiographic outcomes and
ates of revascularization in 2 cohorts of patients under-
oing PCI with paclitaxel-eluting stents (14) (187
omen and 475 men) and sirolimus-eluting stents (15)
Figure 2. Stent Thrombosis
Cumulative event rates of deﬁnite (A) and deﬁnite or probable (B) stent throm
coronary intervention.249 women and 629 men) in the setting of “on-label”indications. Onuma and coauthors reported comparable
rates of death, MI, and target vessel revascularization in
798 women and 2,007 men treated with sirolimus-eluting
or paclitaxel-eluting stents within the RESEARCH
(Rapamycin-Eluting Stent Evaluated at Rotterdam Car-
diology Hospital) and T-SEARCH (Taxus-Stent Eval-
uated at Rotterdam Cardiology Hospital) registries dur-
ing 3-year follow-up (16), and showed a similar benefit of
DES as compared with bare-metal stents in terms of
in women and men through 2 years. PCI  percutaneousbosisrepeat revascularization among women and men. Similar
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308observations came from the TAXUS Woman analysis
(17), comparing outcomes between 665 women and
1,606 men treated with paclitaxel-eluting or bare-metal
stents included into 5 randomized clinical trials in an
“on-label” setting, as well as 1,528 women and 3,266 men
with an “expanded” indication within 2 large “real-world”
registries. The present study extends the available evi-
dence to a large and homogenous cohort of women and
men who were treated with the unrestricted use of DES
in an all-comers patient population, including ST-
elevation MI, and a high prevalence of “off-label” indi-
cations. The similar outcomes in terms of cardiac death,
MI, and stent thrombosis are reassuring and reinforce the
lack of a sex gap in terms of patient and device safety.
Along the same line, the present study provides robust
Table 5. Stent Thrombosis Through 2 Years
Women
(n  1,164)
Men
(n  3,72
Deﬁnite
Early (0–30 days) 15 (1.3) 37 (1.0)
Late (31 days-12 months) 3 (0.3) 9 (0.2)
Very late (12 months) 2 (0.2) 16 (0.4)
Overall 20 (1.7) 62 (1.7)
Deﬁnite or probable
Early (0–30 days) 19 (1.6) 51 (1.4)
Late (31 days-12 months) 4 (0.3) 12 (0.3)
Very late (12 months) 3 (0.3) 17 (0.5)
Overall 26 (2.2) 80 (2.2)
Values are n (%).
Abbreviations as in Tables 2 and 3.
Table 6. Angiographic Follow-Up
Women Men Differen
Lesions, n 351 1,210
RVD, mm 2.76 0.60 2.76 1.11 0.01 (
MLD, mm
In-stent 2.30 0.73 2.29 1.36 0.01 (
In-segment 2.09 0.75 2.10 1.40 0.03 (
Stenosis, %
In-stent 18.1 19.9 18.3 37.0 0.24 (
In-segment 24.4 21.2 23.9 39.4 1.09 (
Late loss, mm
In-stent 0.18 0.54 0.20 0.99 0.01 (
In-segment 0.16 0.56 0.18 1.04 0.00 (
Binary restenosis
In-stent 21 (6.1) 64 (5.4) 0.72 (
In-segment 29 (8.5) 100 (8.5) 0.01 (
Values are mean SD or n (%).Abbreviations as in Tables 2 and 3.evidence that DES achieve comparable efficacy in women
and men. Rates of clinical revascularization showed no
difference despite a somewhat lower baseline reference
vessel diameter among women. Moreover, detailed an-
giographic analysis showed similar acute and long-term
performance of DES irrespective of sex as evidenced by
comparable post-procedural and follow-up minimal lu-
men diameter dimensions (Fig. 4). Finally, the results
confirm similar potency of DES in the suppression of
neointimal hyperplasia as evidenced by the in-stent late
loss and in-segment restenosis. Mehilli et al. have previ-
ously described a lower risk of clinical and angiographic
restenosis in women as compared with men undergoing
PCI using bare-metal stents (6). Conversely, we observed
a similar risk of angiographic and clinical restenosis
Crude Adjusted
OR (95% CI) p Value OR (95% CI) p Value
1.27 (0.69–2.32) 0.44 0.54 (0.21–1.34) 0.18
1.05 (0.28–3.89) 0.94 1.85 (0.39–8.76) 0.44
0.40 (0.09–1.77) 0.23 0.47 (0.05–4.57) 0.52
1.02 (0.61–1.69) 0.95 0.68 (0.33–1.39) 0.29
1.18 (0.69–2.01) 0.54 0.52 (0.22–1.20) 0.13
1.05 (0.34–3.26) 0.94 1.68 (0.44–6.39) 0.45
0.57 (0.17–1.95) 0.37 0.98 (0.18–5.45) 0.98
1.03 (0.66–1.62) 0.89 0.73 (0.38–1.38) 0.33
Crude Adjusted
5% CI) p Value Difference (95% CI) p Value
to 0.05) 0.72 0.00 (0.07 to 0.06) 0.88
to 0.07) 0.83 0.01 (0.09 to 0.07) 0.80
to 0.05) 0.46 0.02 (0.10 to 0.06) 0.60
to 2.35) 0.82 0.72 (1.60 to 3.05) 0.54
to 3.34) 0.34 1.26 (1.30 to 3.82) 0.33
to 0.05) 0.76 0.00 (0.06 to 0.07) 0.97
to 0.06) 0.98 0.00 (0.07 to 0.06) 0.93
to 2.82) 0.50 1.47 (2.05 to 4.99) 0.41
to 4.67) 0.76 0.49 (5.89 to 6.87) 0.651)ce (9
0.08
0.09
0.11
1.87
1.15
0.07
0.06
1.38
4.65
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309among women and men irrespective of the type of DES
used, indicating that DES efficacy is largely independent
of patient sex.
Recently, 2 large investigations underscored sex differ-
ences in delivery of evidence-based therapies and clinical
outcomes among patients with coronary artery disease
(25,26). In the present study, women presented with more
advanced age and a greater prevalence of diabetes and
hypertension, resulting in an overall higher clinical risk
profile at baseline. The latter contributed to higher crude
event rates among women, which were no longer apparent
following adjustment for differences in baseline characteris-
tics. The present study does not address why women present
later and have a higher clinical risk profile at the time of
Figure 3. Angiographic Outcomes Among Women and Men
Cumulative frequency of in-stent late loss (A) and rates of in-segment
binary restenosis (B) among women and men at the time of follow-up
angiography.revascularization. However, it is notable that the angio-graphic risk as assessed by the SYNTAX score was lower
among female than male patients, suggesting that the extent
of coronary artery disease was less severe despite the more
unfavorable clinical characteristics.
Study limitations. First, this is an analysis of individual
patient data pooled from 3 randomized clinical trials not
primarily intended to investigate sex-based differences in
outcomes. However, the large number of included patients
provides sufficient precision to evaluate differences between
women and men in a large spectrum of patients. Second, 5
different types of DES were used for implantation in 3
different studies. However, we analyzed differences by the
use of mixed models accounting for the different studies
included in the present analysis as well as treatment arms.
Moreover, the use of different types of DES provides a
certain degree of generalizability of our findings to DES as
a class treatment effect. Finally, the angiographic follow-up
was not available for all included patients. Nevertheless, the
consistency of angiographic results and the correlation with
clinical efficacy support our findings of equivalent efficacy of
DES in women and men undergoing PCI.
Conclusions
The unrestricted use of DES is associated with similar
long-term safety and efficacy among women and men with
coronary artery disease requiring revascularization.
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